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 23 
Abstract 24 
Antibodies are very efficient drugs, about 70 of them are already approved for medical use, 25 
over 500 are in clinical development, and many more are in preclinical development. One 26 
important step in the characterization and protection of a therapeutic antibody is the 27 
determination of its cognate epitope. The gold standard is the 3D structure of the antibody-28 
antigen complex by crystallography or NMR. However, it remains a tedious task and its 29 
outcome is uncertain. We have developed MAbTope, a docking-based prediction method of 30 
the epitope associated with straightforward experimental validation procedures. We show 31 
that MAbTope predicts the correct epitope for each of 129 tested examples of antibody-32 
antigen complexes of known structure. We further validated this method through the 33 
successful determination of the epitopes recognized by two therapeutic antibodies targeting 34 
tumor necrosis factor α (TNF-α): certolizumab and golimumab. 35 
  36 
 3 
Introduction 37 
The use of antibodies (Abs) as drugs against a large number of diseases has dramatically 38 
increased in the last decade, and this tendency should still intensify in the near future (1). 39 
Because many antibodies are often developed against a same target, it has become essential 40 
to determine the epitope of an antibody early in its development. Moreover, the 41 
identification of the epitope is an important element in the understanding of Ab mechanism 42 
of action (2). 43 
Aside from 3D structures, most experimental methods available for epitope determination 44 
are based either on (i) site-directed mutagenesis; (ii) peptide arrays (3–5) or (iii) mass 45 
spectrometry (6). Most peptide-based methods use 15-30 amino acids overlapping peptides 46 
of the target arrayed on solid support, which are then exposed to the antibody (4, 5). This 47 
identification of interacting peptides can then be completed by alanine-scanning in order to 48 
define the epitope more precisely (3). In the mass spectrometry-based approach, the 49 
antibody-antigen complex is subjected either to hydrogen/deuterium exchange (HDX-MS) 50 
(7), or to enzymatic digestion, which allows differentiating target peptides that are 51 
“protected” by the presence of the antibody. These peptides can then be identified using 52 
mass spectrometry (see (6) for a review). It should be noted that even when successful, 53 
these different approaches are likely to provide non-identical definitions of the epitope. 54 
Indeed, because of the crystallisation step that freezes the complex structure in one out of 55 
many possible conformations, X-ray structure identifies only the most stable interactions. 56 
Alanine scanning does not allow identifying all the interacting residues for different reasons: 57 
the mutated amino acid might interact with the antibody through its main chain or the 58 
mutation to alanine might not be drastic enough to give rise to a measurable difference in 59 
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affinity. Still, there is usually a large overlap between the epitopes identified by each method, 60 
which corresponds to the core of the interface. 61 
However, these approaches are expensive, time-consuming and, except crystallography, 62 
remain error-prone. Indeed, the results obtained through HDX-MS are sometimes very 63 
difficult to interpret, for example when there is a conformational change in the target 64 
between the free and complexed forms (7). Peptide arrays performance at identifying 65 
epitopes are limited by different factors (8): immobilization methods, affinity of the peptides 66 
and conformational constraints induced by the immobilization. For these reasons, many 67 
efforts have been put in developing in silico methods capable of predicting antibody-antigen 68 
interactions. This endeavour has taken two main directions: (i) B-cell epitope prediction, 69 
which aims at predicting the regions of a protein that are the most amenable of being 70 
targeted by an antibody; and (ii) partner-specific approaches, which aim at predicting the 71 
epitope for a single antibody-target pair (see (9, 10) for reviews). Only the second type of 72 
method leads to the prediction of the epitope for a given antibody, though B-cell epitope 73 
prediction can be a useful first step in this process. Amongst the partner-specific approaches, 74 
three main categories can be distinguished: predictors based on the intrinsic properties of 75 
the partners, predictors based on co-evolution of the partners, and predictors based on 76 
docking. However, few of these methods are dedicated to the special case of antibody-77 
antigen interaction.  78 
The aim of docking methods is originally the prediction of the conformation of the assembly 79 
between two interacting proteins. From a correct prediction of this conformation, the 80 
interaction regions can be straightforwardly defined. For this reason, docking methods have 81 
been applied to the prediction of interaction interfaces, and in some cases the specific issue 82 
of predicting the epitope and the paratope. Some methods provide accurate results, such as 83 
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Rosetta (11) and Z-dock (12), but in local docking only, meaning that they require a partial 84 
knowledge of the epitope. The introduction of sDARS, a pairwise statistic potential specific of 85 
antibody-antigen interactions, allows PIPER/Cluspro (which is the algorithm used for docking 86 
within the Bioluminate suite) to achieve satisfactory results (13), placing at least one near-87 
native solution in the top-10 predicted conformations. The particularity of this statistic 88 
potential as compared to previously used ones is that it accounts for the asymmetry of the 89 
antibody-antigen interaction. Another example of a web-server specific for antibody-antigen 90 
docking is Frodock (14, 15). Frodock uses spherical harmonics for conformation generation 91 
(as opposed to fast-Fourier transform for most other algorithms, including PIPER), and a 92 
combination of energetic (van der Waals, electrostatics and desolvation) and knowledge-93 
based potentials, optimized for the different categories of complexes (enzyme, antibodies 94 
and others). However, the goal of these methods is predicting the conformation of the 95 
assembly, meaning predicting the interaction region, but also the precise relative 96 
orientations of the two partners, and not predicting the epitope. Even though they perform 97 
better at this task than the other types of epitope prediction methods, they are not 98 
optimized for it. 99 
We have developed a new method for epitope determination, named MAbTope, which 100 
integrates both a docking-based prediction method and experimental steps. Indeed, the 101 
software part of the method automatically outputs peptides, without any human 102 
intervention, that can be readily used for experimental validation. We also show how these 103 
peptides can be used to design point mutations in the target, allowing a more precise 104 
definition of the epitope. Thus, this method, although in part computational, is not just a 105 
prediction method, but also includes the experimental validation of the epitope. 106 
  107 
 6 
Material and methods 108 
Overview of the method 109 
The 3D structures of the antibody and of the target are used as input of the Hex software 110 
(16) (Figure 1). Hex generates more than 108 docking poses and ranks them according to 111 
energetic criteria (H-ranking). Each of the Hex top-500 docking poses is evaluated using 30 112 
specific and 30 non-specific scoring functions. The non-specific scoring function is identical 113 
to the one used in PRIOR (17), the specific scoring function has been re-optimised, using the 114 
learning dataset described hereafter, and the same machine-learning procedure: genetic 115 
algorithm and CMA-ES (18), and in both cases the area under the ROC-curve is used as 116 
fitness function. A consensus score is then computed using the formula: 117 
𝐶𝑂𝑁𝑆(𝑖) = 𝑘*2 	. .𝑙𝑛 1∑ 𝑟𝑎𝑛𝑘567(𝑖)895:;∑ 𝑟𝑎𝑛𝑘567(0)895:; = + 	𝑙𝑛 1∑ 𝑟𝑎𝑛𝑘57(𝑖)895:;∑ 𝑟𝑎𝑛𝑘57(0)895:; =? 118 
Where 𝑟𝑎𝑛𝑘567(𝑖) is the ranking of pose i according to the non-specific function j, and 119 ∑ 𝑟𝑎𝑛𝑘57(𝑖)895:;  is the ranking of pose i according to the specific function j.	The rankings of 120 
pose 0 (the best ranked according to Hex) are used for normalization. 121 
For each pose, the algorithm also computes the A-score, C-score and P-score (see hereafter). 122 
For each residue r of the target, we compute a value, Vr, which is the sum of the Hex ranks 123 
of the poses in which r belongs to the interface. For a given pose, the A-score is the sum of 124 
the Vr of the residues that belong to the epitope in this particular pose. For each pose, the C-125 
score is the sum of the ranks of the other poses that have a RMSD value lower than 5 Å with 126 
this particular pose. 127 
The consensus, Hex-rank, A-score, C-score and P-score are used to generate 5 different 128 
rankings. For each pose, the sum of its ranks in the different rankings is computed. These 129 
numbers are used to generate the final ranking. The top 30 solutions are then used to 130 
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compute the interface frequency (IF) of each residue of the target, which is equal to the 131 
number of poses within these 30 in which the residue belongs to the interface. This IF is used 132 
to design the interface peptides (see hereafter). 133 
P-score 134 
A new post-processing function has been introduced: the P-score. For a given docking pose, 135 
we count the number of CDR amino acids that are closer than 4Å to an atom of the target, 136 
and normalize by the total number of CDR residues. The docking poses are then ranked by 137 
decreasing values of this ratio. This rank is the P-score of the pose. 138 
Specific learning dataset 139 
The learning dataset is composed of 393 non-redundant antibody-target complexes 140 
manually extracted from the PDB in January 2015. Only the complexes in which the target is 141 
larger than 40 residues were considered. These complexes contain 392 distinct Abs and the 142 
targets belong to 165 distinct Pfam families. The definition of non-redundancy we use is 143 
weaker than what is usually used, since antibodies are very special proteins, and overall 144 
sequence identity, even restricted to the variable domain, is not indicative of the antibody 145 
specificity, and consequently on its ability to form a complex with its target. The criteria 146 
retained for considering two Ab-Ag complexes as non-redundant were: (i) targets are not 147 
related (they belong to different Pfam families); or (ii) targets are related but the epitopes 148 
recognized by the antibodies have less than 20% overlap; or (iii) targets are related and 149 
epitopes are overlapping but the CDRs of the considered antibody differ in 10 or more 150 
positions. This third criterion is justified by the fact that most pairs of antibodies differing by 151 
10 or more residues within the CDRs, even when they present a very high overall sequence 152 
identity, do not share the same target.  153 
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Test dataset 154 
To evaluate the performance of the method, a test dataset has been designed. It consists in 155 
the 82 complexes of the learning dataset for which the 3D structures of the individual 156 
partners are known. For the evaluation, the learning has been done in leave-one-out, 157 
meaning that the epitope of a given antibody is predicted using a scoring function learnt on 158 
a dataset not containing the 3D structure of the complex it forms with its target. Forty-seven 159 
new complexes whose 3D structure has been determined after January 2015, and which 160 
were non-redundant with those already present in the learning dataset have been added to 161 
this test set.  162 
We distinguished “small” targets (40 to 300 amino acid long) from “large” targets (more than 163 
300 amino acid long). However, the results obtained for the two categories only slightly 164 
differ. 165 
Negative controls 166 
In order to better evaluate the method performance, we have included negative controls. To 167 
this aim, we have compared, for each target of the test set, the epitope predicted by docking 168 
each of the non-cognate Abs of the test set to the actual epitope. 169 
Epitope definition 170 
In this work, an amino acid of a protein targeted by an antibody will be considered as 171 
belonging to the epitope if at least one of its atoms is at less than 4 Å of an atom belonging 172 
to an amino acid of the antibody. These distances are computed on the crystallographic 173 
structure of the complex. 174 
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Definition of epitope peptides 175 
Each amino acid of the target is attributed a value, which is the number of poses within the 176 
30 top-ranked ones in which this amino acid belongs to the predicted epitope. Different sizes 177 
of pose sets have been tested, and 30 is a satisfactory compromise (data not shown). Each 178 
15 amino acid peptide of the sequence is then given a score equal to the sum of these values 179 
for each amino acid in the peptide. The peptides are then ranked along this score. Peptides 180 
overlapping by at least 8 amino acids with a better-ranked peptide are ignored. For 181 
benchmarking, the relevance of a given peptide is evaluated by the number of residues that 182 
belong to the crystallographic epitope. This definition of epitope peptide was also used for 183 
the testing of Cluspro and FRODOCK. In EpiPred predictions, amino acids present in the first 184 
predicted epitope were given a score of 3, a score of 2 for the amino acids of the second 185 
epitope and a score of 1 for the amino acids of the third epitope. In PPiPP predictions, the 186 
scores given in the program output were considered. Epitope peptides were then built as 187 
explained above. 188 
The choice of 15 mers is a compromise between two empirical observations we have made 189 
along the development of this method. (i) Shorter peptides tend to give a poor signal. Our 190 
hypotheses are that they are too flexible (short peptides present less long-range interactions 191 
and are thus more flexible), which decreases their binding to the antibody. Moreover, the 192 
secondary structure is important for binding, and very short peptides have no chance to 193 
adopt hairpin or strand conformations. (ii) Longer peptides tend to span over more than one 194 
loop, and interpretation of experimental results is then more difficult. A second aspect is 195 
that longer peptides have a higher tendency to precipitate.  196 
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Evaluation criteria 197 
MAbTope first output is a ranked list of docking poses. To evaluate the distance between 198 
these poses and the native solution, CAPRI criteria were used (19): 199 
• High quality (***): fnat>0.5 AND (Irmsd<1 OR Lrmsd<1); 200 
• Medium quality (**): [fnat ε[0.3, 0.5] AND (Irmsd<2 OR Lrmsd<5)] OR [fnat>0.5 AND 201 
Irmsd>1 AND Lrmsd>1]; 202 
• Acceptable (*): [fnat>0.3 AND Irmsd>2 AND Lrmsd>5] OR [fnat ε[0.1, 0.3] AND 203 
(Irmsd<4 OR Lrmsd<10)]; 204 
where fnat is the fraction of correctly predicted contacts, Lrmsd (Ligand RMSD) is the RMSD 205 
between the predicted position of the ligand and its position in the crystal structure, Irmsd 206 
(Interface RMSD) is the same but reduced to the interface residues. 207 
Since our epitope predictions are based on the evaluation of a set of conformations, and not 208 
on a single conformation, it was necessary for us to also evaluate the number of “indicative” 209 
conformations: 210 
• Indicative (+): [fnat>0.1] OR [Lrmsd< 10] OR [Irmsd < 5] 211 
Introducing this new category is very useful for evaluating docking performance in the 212 
perspective of epitope determination. Indeed, the docking poses falling in this category, 213 
even though their geometry is too distant from the crystal structure to be considered as 214 
acceptable by the Capri criteria, still define an interaction area on the target that overlaps 215 
with the actual epitope, and thus give valuable information on the epitope. 216 
To evaluate the docking performances of our algorithms, for each complex in the test set we 217 
calculate the rank of the first near-native pose with the CAPRI criteria and with our own 218 
criteria (CAPRI + indicative).  219 
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The second output of MAbTope is a list of peptides, ranked on the predicted probability they 220 
match with the epitope. To evaluate the epitope prediction accuracy, we calculate the 221 
number of residues in each peptide that belong to the actual epitope (and do not belong to 222 
better ranked peptides), normalized by the total number of residues in the epitope.  223 
Binding kinetics of certolizumab to biotinylated peptides using biolayer interferometry 224 
(BLI) 225 
All measurements were performed with the Octet RED96 System (Pall Forte Bio, Fremont, 226 
CA, USA), in the manufacturer kinetics buffer, at 30 °C, with shaking at 1000rpm. 227 
Biotinylated peptides were immobilized during 200 seconds on streptavidin-coated sensors 228 
(SA) at 0.5, 1 and 5 µg/mL for P1-3, P1-1 and P1-2 respectively and left for equilibration for 229 
120 seconds in kinetics buffer. Typical capture variability within a row of eight tips did not 230 
exceed 0.1 nm. Binding was assessed at 100, 200, 400, 600, 800, 1000 and 1200 µg/mL 231 
certolizumab for 300 seconds. Two parallel corrections were carried out by subtracting the 232 
association of certolizumab on an immobilized non-relevant biotinylated peptide, and by 233 
subtracting the loading baseline drift on non-associated sensors. Data were analyzed using 234 
Octet Software 9.0 version. Since certolizumab is a Fab’, experimental data were fitted with 235 
the binding equation describing a 1:1 interaction. Considering the weak affinity of peptides 236 
for the antibody and the fact that the dissociation is almost immediate, we restrained the 237 
dissociation analysis to the 20 first seconds. Global analyses of the datasets assuming that 238 
binding was reversible (full dissociation) were carried out using nonlinear least-squares 239 
fitting, allowing a single set of binding parameters to be obtained simultaneously for all 240 
concentrations used in each experiment. 241 
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HTRF-based competition assay 242 
The competition between Golimumab and either the Certolizumab or the peptides for the 243 
TNFα was assessed in vitro using an HTRF®-based assay in 384-well plate. The Golimumab 244 
and the Certolizumab were kindly provided by Denis Mulleman (CHRU Bretonneau, Tours, 245 
France). The Golimumab was incubated at 0.1, 0.33 and 1 nM with 8 ng of TNFα 246 
(NP_000585.2, Val77-Leu233) N-terminally fused to the AviTag® (Avidity LLC, Aurora, CO, 247 
USA) purchased from ACROBiosystems (Newark, DE, USA) in 10 µl of PPI - Terbium detection 248 
buffer (CisBio Bioassays, Condolet, France). Five microliters containing either 4 mM of non-249 
biotinylated peptides (GeneCust, Dudelange, Luxembourg) or 4 µM of Certolizumab were 250 
added. The HTRF-compatible fluorophore Terbium cryptate and d2 conjugated to either an 251 
anti-Fc Ab or the streptavidin (from CisBio Bioassays, Condolet, France) were finally added in 252 
5 µl. After 1h incubation at room temperature, the fluorescence at 620 nm and 665 nm were 253 
measured on the TriStar² LB 942 microplate reader (Berthold Technologies GmbH & Co, 254 
Wildbad, Germany). Data were expressed as the emission ratio 665 nm / 620 nm subtracted 255 
by the non-specific signal obtained without Ab nor peptide. 256 
Interaction measurement by peptide array 257 
Peptide array: 258 
The interaction between the different biotinylated peptides (GeneCust, Dudelange, 259 
Luxembourg) and golimumab was assessed in vitro using peptide array. Biotinylated 260 
peptides are first diluted in printing buffer (20 % Glycerol and 1 M DMSO) for a final 261 
concentration of 0.8 nM and 1.6 mM. Peptides spotted in two replicates in 16 identical sub-262 
arrays on a nitrocellulose coated glass slide (ONCYTE® Film slides, Grace Bio-Labs, USA) using 263 
a Nano-Plotter (GeSIM, Germany). Slides are dried overnight at room temperature.  264 
Preparation of antibodies: 265 
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Golimumab is fluorescently labelled with iFluor™ 680 amine dye (AAT Bioquest, USA) 266 
following the protocol of the provider. Excess of dye are eliminated by centrifugation on 267 
Amicon Ultra filter (Merck Millipore, Darmstadt, Germany). Antibodies are prepared fresh 268 
for the incubation by diluting into PBS-T (PBS 1 X, 0.1 % Tween 20) supplemented with 1% of 269 
BSA (Sigma) for a final concentration of 2 ng/ml. 270 
Incubation: 271 
Slides are mount with Pro-Plate® chamber (Grace Bio-Labs, USA) for the following steps. 272 
Slides are hydrated with 150 µl per well of PBS-T solution for 15 min under agitation on a 273 
seesaw rocker. PBS-T is removed and 100 µl of Super G blocking buffer (Grace Bio-Labs, USA) 274 
is added for 1h incubation on a seesaw rocker. After removing the blocking buffer, 100 µl per 275 
well of antibodies diluted in PBS-t supplemented with 1 % BSA (corresponding to 200 ng) are 276 
added for 2 h incubation on a seesaw rocker. Then, antibodies are removed and slides are 277 
washed two times with PBS-T for 5 min and once with PBS (150 µl/well). Finally, slides are 278 
rinsed with filtered water for one minute and air-dried. 279 
Detection and analysis: 280 
Slides are scanned with an InnoScan 710-IR scanner (Innopsys, France) at 670 nm 281 
wavelength, 3 µm resolution, PMT of 1 and low intensity of the laser. Image analysis is 282 
performed using the circular feature alignment of Mapix software (Innopsys, France). 283 
Relative Fluorescence Unit (RFU) is obtained by retrieving the median fluorescence signal 284 
intensity of surrounding each feature to the median fluorescent signal of the feature. RFU is 285 
used to measure the interaction between the different peptides and the antibody. Graphs 286 
are generated using GraphPad Software (GraphPad Prism 5 Software, San Diego, CA, USA). 287 
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In vitro FRET binding measurement 288 
The interaction between the different biotinylated peptides (GeneCust, Dudelange, 289 
Luxembourg) and Certolizumab, or Golimumab, or Eculizumab used as a negative control, 290 
was assessed by HTRF®. All experiments were performed in PPI-Terbium or -Europium 291 
detection buffers (CisBio Bioassays, Condolet, France). For this, 5 µL of biotinylated peptides 292 
(4 mM) were first incubated with 5 µL of either of the mAbs (1.6 µg/mL) for 1 hr at room 293 
temperature. Then, 5 µL of streptavidin and 5 µL of anti-Fab (for Certolizumab) or anti-Fc 294 
(for Golimumab and Eculizumab) antibodies conjugated with HTRF compatible fluorophores, 295 
Terbium or Europium cryptate and d2, were added in quantities recommended by the 296 
manufacturer. After an overnight incubation at 4°C, the fluorescence emissions at 620 nm 297 
and 665 nm were measured using the appropriate HTRF program on a TriStar² LB 942 298 
Modular microplate reader (Berthold Technologies GmbH & Co. Wildbad, Germany). Data 299 
are represented as specific FRET signals calculated as the 665 nm/620 nm emission ratio 300 
subtracted of the binding on the non-relevant Ab. 301 
 302 
Golimumab binding on mutant TNFα by flow cytometry 303 
Three TNFα mutants were designed starting from the sequence NP_000585.2 by 304 
incorporating the mutations predicted to alter the interaction with Golimumab according to 305 
our docking solution. The mutant TNFα constructions contain the following mutations: 306 
TNFα_P1-1m6 (N222A, R223A, D225A, F229A, E231A, Q234A), TNFα_P3-1m7 (R167A, Y172A, 307 
Q173A, T174A, K175A, N177A), and TNFα_P4-1m6 (Q106A, E108A, Q110A, Q112A, R116A). 308 
The cDNA of the 3 mutants and the wild-type TNFα fused to a Flag tag on their N-terminus 309 
and depleted of the 77 first residues which contain the transmembrane part of the protein 310 
targeted by proteases, were synthesized and subcloned in pcDNA3.1 by GenScript 311 
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(Piscataway, NJ 08854, USA). HEK293N cells were transiently transfected with the TNFα 312 
constructions or a mock vector using Metafectene (Biontex Laboratories GmbH, München, 313 
Germany) according to manufacturer’s instructions. Thirty hours after transfection, the cells 314 
were fixed and permeabilized according to the BD Cytofix/Cytoperm kit instructions (BD 315 
Biosciences, San Jose, CA, USA). All the following hybridations were performed in the kit’s 316 
perm/wash buffer. Five hundred thousand cells of each transfected population were 317 
incubated with 5 µg of Golimumab for 1 hr at room temperature and washed once in 2 ml 318 
buffer. The binding of Golimumab was assessed with the allophycocyanin (APC)-labelled 319 
anti-IgG1 antibody from Miltenyi Biotech (Bergisch Gladbach, Germany) diluted to 1:100.  320 
The expression level of each of the constructions was evaluated with and anti-Flag Ab 321 
coupled to phycoerythrin (PE) also from Miltenyi Biotech (Bergisch Gladbach, Germany). 322 
After staining, all the cells were washed once in 2 ml working buffer and once in 2 ml PBS- 323 
EDTA 2 mM and finally suspended in 200 µl of PBS-EDTA 2 mM. The fluorescence was 324 
assessed with the MACSQuant Analyzer 10 (Miltenyi Biotec, Bergisch Glabach, Germany) and 325 
the data analyzed with FlowJo software (FlowJo LLC, Ashland, OR, USA).  326 
 327 
Binding kinetics of Certolizumab to biotinylated peptides using biolayer interferometry 328 
(BLI) 329 
All measurements were performed with the Octet RED96 System (Pall Forte Bio, Fremont, 330 
CA, USA), in the manufacturer kinetics buffer, at 30 °C, shaking at 1000 rpm. Biotinylated 331 
peptides were immobilized during 200 seconds on streptavidin-coated sensors (SA) at 0.5, 1 332 
and 5 µg/mL for C1-3, C1-1 and C1-2 respectively and left for equilibration for 120 seconds in 333 
kinetics buffer. Typical capture variability within a row of eight tips did not exceed 0.1 nm. 334 
Binding was assessed at 100, 200, 400, 600, 800, 1000 and 1200 µg/mL Certolizumab for 300 335 
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seconds. Two parallel corrections were carried out by subtracting the association of 336 
Certolizumab on an immobilized non-relevant biotinylated peptide, and by subtracting the 337 
loading baseline drift on non-associated sensors. Data were analyzed using Octet Software 338 
9.0 version. Since Certolizumab is a Fab’, experimental data were fitted with the binding 339 
equation describing a 1:1 interaction. Considering the weak affinity of peptides for the 340 
antibody and the fact that the dissociation is almost immediate, we restrained the 341 
dissociation analysis to the 20 first seconds. Global analyses of the datasets assuming that 342 
binding was reversible (full dissociation) were carried out using nonlinear least-squares 343 
fitting, allowing a single set of binding parameters to be obtained simultaneously for all 344 
concentrations used in each experiment. 345 
 346 
Statistical analysis 347 
Experimental data were analysed under Prism 6 software (GraphPad Software, La Jolla, CA, 348 
USA). Data were expressed as mean ± sem and ANOVA statistical analysis was applied.   349 
 17 
Results  350 
Principle and Benchmarking 351 
MAbTope involves three successive steps. The first step is the docking of the antibody on its 352 
target, which results in the generation of docking poses (possible conformations of the 353 
antibody-antigen complex), through a method related to PRIOR, a general protein-protein 354 
docking method we had previously developed (17, 21, 22). The second step is the ranking of 355 
these docking poses in order to extract 30 poses that tile the epitope, and the design of four 356 
so-called interacting peptides, that is, peptides predicted to be part of the epitope. The third 357 
step is the experimental validation based on the interacting peptides. Different methods can 358 
be used: measurement of the binding of each of these four peptides with the antibody, 359 
competition for antibody binding between the peptides and the target, or measurement of 360 
the binding of target mutated on residues belonging to these peptides. 361 
The design of the interacting peptides from the docking poses is crucial for the success of the 362 
method. At this step, all the possible 15 amino acid-long peptides of the target are ranked 363 
according to the frequency at which their amino acids are found within the epitope in the 30 364 
top-ranked docking poses. MAbTope predicts a correct peptide, that is, a peptide that 365 
contains residues belonging to the crystallographic interface, within the 4 best-ranked ones 366 
for all of the 129 complexes tested. On average the 4 best-ranked peptides contain more 367 
than 80% of the epitope residues, and the minimum is 30%, meaning that the epitope is at 368 
least partly found for all complexes in the test set (Figure 1A, Table S1). As a control, each 369 
antibody of the test set was docked to all the targets of the other antibodies. In this test, on 370 
average only 36 % of the residues belonging to the epitope of the specific antibody are 371 
found within the 4 best-ranked peptides.  372 
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MAbTope performs much better than Cluspro or FRODOCK at predicting the epitopes, as 373 
they identify, within the 4 best-ranked peptides, 36 % and 35 % of the epitope residues 374 
respectively. One reason is that, in MAbTope, the 30 top docking poses are centred on the 375 
correct epitope, and not distributed on the whole surface of the target. This is illustrated in 376 
Figure 2 (see also Figures S1, S2) by the example of the complex between the HIV gp120 377 
glycoprotein and the VRC03 antibody (PDB 3SE8) (23). This particularity, which can be found 378 
for all of the tested examples, arises for two main reasons. First, for conformation 379 
generation, we use Hex with very restrictive angle parameters, the obtained poses are 380 
consequently already well focused. Second, the A-score (as defined in materials and 381 
methods) favours over-represented poses, and consequently decreases the diversity of the 382 
top-ranked poses. As a result, the amino acids constituting the epitope are almost all found 383 
in more than half of the 30 selected docking poses. Consequently, the four best ranking 384 
peptides all contain amino acids belonging to the interface (Figure S3). In addition, peptides 385 
1 and 2 contain 7 and 6 amino acids belonging to the epitope, respectively. It should be 386 
noted that peptides 3 and 4 also contain 8 and 6 residues, respectively, and can also be 387 
considered as good predictions. Finally, the 6 best-ranking peptides contain all the amino 388 
acids belonging to the epitope. 389 
We also compared the performance of MAbTope to that of two non-docking-based epitope 390 
prediction methods: PPiPP (24) and EpiPred (25). The results show that MAbTope clearly 391 
outperforms these two methods, confirming that a detailed consideration of shape and 392 
electrostatic complementarity, which results from the docking procedure, is necessary for 393 
high quality predictions (Figure 1B, Table S1).  394 
The last step of the method consists in the experimental validation. Our first approach 395 
consists in measuring the binding of the antibody to the peptides. For each designed peptide, 396 
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three peptides are synthesized, all of the same length but sliding three amino acids along the 397 
sequence. The first one starts and ends 3 amino acids upstream of the designed epitope 398 
peptide, the second one corresponds to the designed one, and the third one starts and ends 399 
3 amino acids downstream. This choice was made to overcome the issue of some peptides 400 
being insoluble. A second approach is to measure the competition between these peptides 401 
and the target for the binding of the antibody. Finally, as the residues present within these 402 
peptides are those predicted to belong to the epitope, they can be used to predict point 403 
mutations of the target reducing the binding of the antibody.  404 
It should be highlighted that MAbTope is able to find the epitope of each antibody, and not 405 
only the most antigenic sites on the target protein as defined by B-cell epitope prediction 406 
methods. This is well illustrated by the example of gp120, to which 25 antibodies of the 407 
benchmark bind. Whereas some regions of gp120 are targeted by a large number of 408 
antibodies, including some that do not belong to the benchmark since the structure of the 409 
isolated antibody is not known, other regions are also targeted. Accordingly, the interaction 410 
peptides designed through MAbTope are spread on the whole target sequence (Figure 2). 411 
MAbTope correctly builds at least one correct peptide for each of these 25 antibodies, and 412 
two peptides for 19. 413 
Validation on golimumab and certolizumab 414 
To validate the method, we next predicted the epitopes of two therapeutic antibodies 415 
targeting Tumor Necrosis Factor α (TNF-α): golimumab and certolizumab. These two 416 
antibodies are already widely used in clinic, but their respective epitope is still unknown. We 417 
built homology models of the two antibodies and used MAbTope to predict the epitopes 418 
they bind. On the basis of the predicted epitope-antibody interface, four different sets of 419 
peptides have been selected and synthesized (G1 to G4 for golimumab and C1 to C4 for 420 
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certolizumab, Figure 4). The P1 family overlaps with G3 and C4, and corresponds to the 421 
region containing the highest overlap between both predictions. The P4 family overlaps with 422 
C2 and G4. The P3 family overlaps with G1 and C1. Finally, the P2 family does not overlap 423 
with a 4-top predicted peptide, but lies in a region well exposed and predicted by MAbTope 424 
to belong to certolizumab epitope but not golimumab one. Peptides G2 and C3 were ignored 425 
since they are partly buried and have consequently low chances to interact efficiently with 426 
the antibody. 427 
After the initial submission of this paper, the structure of the complex between certolizumab 428 
and TNF-α has been published (26). Comparison with our prediction shows that out of the 20 429 
residues constituting the epitope, 17 belong to peptides C1 to C4 (Figure 3A). This shows 430 
that certolizumab epitope can be considered as conformational since it involves residues 431 
belonging to five different peptides. Nevertheless, we are still able to show the specific 432 
binding of some of these peptides to the antibody through HTRF and interferometry (Figure 433 
S4). 434 
To validate the epitope of golimumab, we first have shown that it competes with 435 
certolizumab for the binding to TNF-α, using HTRF (Figure 4A and S5). We thus performed 436 
further experimental validations on golimumab solely. We have also shown, using both HTRF 437 
and peptide array (RPPA), that golimumab specifically binds the P3-1, P3-2 and P3-3 peptides 438 
(Figures 4B and 4C). Finally, we have shown, using HTRF, that peptides P1-1, P1-2, P1-3, P3-1 439 
and P3-3 decrease the binding of golimumab to TNF-α in a dose-dependent manner. Note 440 
that we observe a strong competition with the P1 series peptides in this last experiment, 441 
whereas we could not observe the binding of these peptides in the direct binding 442 
experiments. One hypothesis is that the biotin, which is attached at the N-ter of the peptide 443 
in the direct binding experiments, could prevent the binding to the antibody. The specificity 444 
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of the binding of the P1 series peptides is confirmed by the flow cytometry experiments 445 
presented hereafter. 446 
To further validate, we mutated in TNF-α the residues belonging to peptides of series 1, 3 447 
and 4 to alanines, and observed the binding of golimumab using flow-cytometry (Figure 5A 448 
and S6). We observed that each TNF-a construct expressed well in cells by detecting flag 449 
epitope that was added to all constructs. Interestingly, we found that the binding of 450 
golimumab its target was almost abolished when the TNF-α was mutated at positions 451 
indicated within P1 and P3 series, and reduced by 50% for mutations within the P4 series 452 
peptides. Finally, for peptides P3-1 and P3-3, which gave the best signals in HTRF, we 453 
mutated individually the residues belonging to these peptides and whose side-chains are 454 
exposed, and measured the binding to golimumab using HTRF (Figure 5C and 5D). These 455 
results show that, as predicted, residues Y172, T174 and K175 are essential for golimumab 456 
binding to TNF-α. 457 
Discussion 458 
The results obtained on the 129 antibody-target complexes of the benchmark show that the 459 
in silico prediction is robust, since within the benchmark, the predicted peptides contain on 460 
average 80 % of the epitopes residues. This number is not much affected by the type of 461 
epitope: 79 % for conformational epitopes (105 out of 129), 89% for linear epitopes (14 out 462 
of 129). Neither is it much affected by the size of target: 88 % for targets up to 300 residues 463 
long, 70 % for larger targets. The main limitation of the in silico step is that the 3D structure 464 
of the target is needed. We have already tested the approach using homology models of the 465 
target when the 3D structure is not available. Although good results could be obtained is the 466 
few tested cases, this requires further investigations.  467 
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Based on the designed peptides, we present three different experimental validations of the 468 
predicted epitope. Our first approach consists in measuring the direct binding of the 469 
designed peptides, either through HTRF, peptide array or through interferometry. Good 470 
results could be obtained for the golimumab peptides of series 3. However, no signal is 471 
observed for series 1 peptides, although we later demonstrate that these peptides belong to 472 
the epitope. The second approach consists in making a competition between the peptides 473 
and the target for the binding of the antibody. Using this method we were able to validate 474 
the peptides of series 1, and confirm the peptides of series 3. Nevertheless, both approaches 475 
are limited by the fact that some peptides tend to be “sticky”. Another limit to these 476 
approaches is the solubility of peptides, which is not always sufficient. 477 
Importantly, the interaction peptides can also be used to design point-mutations in the 478 
target potentially decreasing the affinity of the antibody. In the TNF-α we mutated to 479 
alanines the residues belonging to peptide series 1, 3 and 4 whose side-chains point towards 480 
the solvent. We show using flow cytometry that these mutations indeed abolish (series 1 481 
and 3) or decrease (series 4) the binding of the antibody. However, this approach also has its 482 
limitations: the difficulty of expressing some target or their mutated forms, especially if they 483 
are toxic for the cells. The endogenous expression of the native target could also raise some 484 
issues. 485 
Despite the known limitations of each experimental approach proposed, it is reasonable to 486 
assume that their combined use will convey more robustness to the overall validation 487 
process. 488 
Further demonstration of MAbTope ability to determine the epitope is given through the 489 
examples of certolizumab and golimumab. For these two antibodies, although their 3D 490 
structure was not known at the beginning of this study, we were able to predict and 491 
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experimentally validate the epitopes. A good example is given by peptide 1.3, which contains 492 
only one residue belonging to the epitope, but for which we were able to measure the 493 
specific binding with certolizumab (Figure S4). Using mutated peptides we were also able to 494 
refine these results, and show the importance of individual residues in the epitope. 495 
Two other therapeutic antibodies are used in clinic for their ability to bind TNF-α: infliximab 496 
and adalimumab, and the 3D structures of the corresponding complexes with the target are 497 
known [4G3Y for infliximab (27) and 3WD5 for adalimumab (28)]. A recent meta-analysis has 498 
compared the efficacy of different TNF-α-blocking agents, including the four antibodies cited 499 
above. It concludes that infliximab and golimumab are less efficient in the treatment of 500 
rheumatoid arthritis than adalimumab and certolizumab (29). By contrast, a meta-analysis 501 
performed in ulcerative colitis indicated that infliximab is better than adalimumab and 502 
probably golimumab (30). Their affinities for TNF-α (4.5 x 10-10 M for infliximab (28), 7.05 x 503 
10-11 M for adalimumab (28), 1.8 x 10-11 M for golimumab (31) and 1.32 x 10-10 M for 504 
certolizumab (US patent US20050042219 A1) do not explain these differences. Hu et al. (28) 505 
hypothesized that the difference of efficacy between infliximab and adalimumab could be 506 
partly due to the fact that adalimumab binds in the groove between two monomers, and has 507 
consequently a higher overlap with the TNF-α receptor binding interface and a better 508 
neutralizing activity, than infliximab, which binds to a monomer. By contrast, the ability to 509 
target inflammatory cells expressing membrane TNF-a, which could be monomeric, and to 510 
induce apoptotic signals seems important determinants of therapeutic activity of anti- TNF-α 511 
agents in inflammatory bowel diseases (32). These reasons could also account for the 512 
difference of efficacy between certolizumab and golimumab, as certolizumab binds in the 513 
groove (like adalimumab), whereas golimumab binds to the monomer (Figure S7), knowing 514 
that certolizumab differs from the three others by its monovalency and the absence of an Fc 515 
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region. However, the fact that the structure of the four anti-TNF-a therapeutic antibodies is 516 
now known will help at understanding the subtle differences in their clinical activities.  517 
 518 
Conclusion 519 
In conclusion, MAbTope initial prediction of the epitope is very robust. On a benchmark of 520 
129 antibody-antigen complexes, MAbTope correctly defines the epitope in each case. In 521 
addition, MAbTope allows defining four 15 amino acid peptides, among which at least one 522 
belongs to the epitope, which in turn allows experimental validation. These peptides also 523 
allow the design of point mutations that can be used to validate and refine the predicted 524 
epitope. Although the information obtained through MAbTope does not allow defining the 525 
precise interactions taking place between the antibody and the target, it allows defining with 526 
good precision the region of the target involved in the interaction. This information is 527 
sufficient for understanding the mechanism of action of the antibody, a crucial step in the 528 
development of therapeutics, but also diagnostic or biotechnological tools. Taken together, 529 
MAbTope is not just a prediction method, but constitutes an integrated workflow allowing 530 
identification of the epitope. With the example of two therapeutic antibodies, certolizumab 531 
and golimumab, we show that it can be successfully applied to antibodies whose 3D 532 
structure is unknown.  533 
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Figure legends 634 
Figure 1: Principle and performance of the method 635 
A: From the 3D structures of the antibody and the target, HEX generates docking poses and 636 
ranks them according to energetic criteria (H-rank). Each of the HEX top-500 docking poses is 637 
evaluated using both non-specific and specific scoring functions. A consensus score is 638 
computed, and the poses are ranked according to this score. In parallel, for each docking 639 
pose, the A-score, C-score and P-score (see hereafter) are computed, and the poses are 640 
ranked. The final ranking of poses is a consensus of the 5 different rankings (HEX, consensus, 641 
A-ranking, C-ranking, P-ranking). The top 30 solutions are used to compute, for each residue 642 
of the target, the frequency at which it appears within the epitope in these top 30 poses, 643 
and to design the epitope peptides. B: Ratio of residues of the epitope within the designed 644 
peptides identified using MAbTope on the complete test set (blue), cluspro (orange), frodock 645 
(green), epipred (violet) and PPiPP (purple). The values obtained when docking the false 646 
positives is shown in red. C: Ratio of epitope residues with the designed peptides identified 647 
using MAbTope on the complete test set (blue), on unique targets (green), on small targets 648 
(orange) and large targets (purple). The values obtained when docking the false positives on 649 
unique targets is shown in red. 650 
 651 
Figure 2: Epitope peptides designed for 25 antibodies targeting HIV gp120. 652 
A: Top-4 epitope peptides designed for the 25 antibodies of the benchmark targeting gp120. 653 
The designed peptides are all mapped on the sequence of 4ZMJ (chains B and G of GP120), 654 
although some of the antibodies target gp120 proteins of different clades. However, the 655 
epitopes recognized by the different antibodies have a homologous region in 4ZMJ. Each 656 
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coloured region represents one designed peptide; a black star indicates that the peptide 657 
belongs to the epitope. Red stars outside of these coloured regions indicate residues of the 658 
epitope that do not belong to a designed peptide. B: 3D structures of the complexes 659 
between the 25 antibodies (cartoon) and gp120 (surface). All the structures have been 660 
superimposed on 4ZMJ, the colour code is given in A. 661 
 662 
Figure 3: Residues present at the interface of docking poses of the Golimumab-TNF and 663 
Certolizumab-TNF complexes. 664 
A: Golimumab: dark blue: residues present at the interface of more than 20 poses, medium 665 
blue: 10 to 20 poses, light blue: 1 to 10 poses. Certolizumab: dark, medium and light violet. 666 
Validation peptides used in experiments are shown below the sequences. First best-ranking 667 
peptides predicted are boxed for each sequence. Red stars indicate the residues of 668 
certolizumab epitope in the crystal structure of the complex. 669 
B and C: selected docking poses for the assembly of TNF-α with golimumab (B) and 670 
certolizumab (C). The three TNF-α monomers are shown in different shades of grey (light, 671 
medium and dark grey). The peptides selected for experimental validation are shown (P1 in 672 
red, P2 in orange, P3 in dark green, P4 in light green). 673 
 674 
Figure 4: Validation of the predicted epitope of golimumab.  675 
A. Certolizumab-induced displacement of Golimumab from AviTag-TNFα and thus bind the 676 
same epitope. The initial binding of Golimumab on AviTag-TNFα was measured at 0.1, 0.33 677 
and 1 nM (brown, orange and red full symbol, respectively) using the HTRF mix anti-IgG-Tb / 678 
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streptavidin-d2. Increasing doses of Certolizumab were added, from 10-15 to 10-5 M (empty 679 
symbols). The IC50 of the displacements are indicated above the graph. 680 
B.C.D. Peptide-based validation assays of Golimumab epitope. B. The 11 peptides predicted 681 
to belong to the epitope at 1 mM, biotinylated at their N-terminus, were incubated with 8 ng 682 
of Golimumab or a non-relevant mAb and the HTRF mix anti-IgG-Tb / streptavidin-d2. The 683 
HTRF signals obtained with Golimumab were corrected by the non-specific binding on the 684 
irrelevant mAb considered as a baseline. C. The 11 predicted peptides and one control 685 
peptide were spotted on a nitrocellulose-coated glass slide. After a blocking step, the slides 686 
were incubated with 200 ng of fluorescently labeled Golimumab. RFU is calculated and used 687 
to compare the interaction between the peptides and the Golimumab. D. Displacement of 688 
the Golimumab from the AviTag-TNFα by the peptides. Selected non-biotinylated peptides at 689 
1, 0.1 or 0.01 mM were incubated with golimumab and biotinylated AviTag-TNFα. The 690 
complex formed by golimumab and TNF-α was detected by the HTRF mix anti-IgG-Tb / 691 
streptavidin-d2. As a displacement control, Certolizumab was incubated with Golimumab / 692 
TNFα complex. HTRF signals were subtracted of the signal obtained with the control 693 
antibody (eculizumab). 694 
 695 
Figure 5: Predicted mutations abolish the binding of Golimumab on complete TNFα and 696 
peptides. 697 
A. HEK293 cells were transfected with either a mock vector, the wild-type TNFα (Val 77 - Leu 698 
233) or with 3 mutated TNFα constructions. The mutations were selected among the amino 699 
acids whose side-chain is solvent-exposed within peptides P1-1, P3-1 and P4-1. Cells were 700 
fixed, permeabilized and incubated with golimumab (0.33 µM). They were then stained by 701 
detection of the Flag epitope fused to the different TNF-α constructs (PE-conjugated anti-702 
 33 
Flag antibody) (upper panels), or of golimumab using an anti-IgG coupled to APC as the 703 
secondary antibody (lower panels). The plots show the side-scatter vs light intensity for both 704 
channels.  705 
B.C.D. Validation of the residues predicted to be implicated in the interaction between 706 
Golimumab and TNFα. Mutated variants of the P3-1 (B) and P3-3 (C) peptides were designed 707 
as indicated. Biotinylated peptides were incubated at 1 mM with 8 ng of either Golimumab 708 
or a non-relevant mAb and the HTRF mix anti-IgG-Tb / streptavidin-d2. The HTRF signals 709 
obtained with Golimumab were corrected by the non-specific binding on the irrelevant mAb 710 
considered as a baseline. D. Summary of the residues found critical in the interaction 711 
between Golimumab and TNFα. In red are indicated the residues obtained from the P3-1 712 
mutants series and in blue the ones from the P3-3 mutants series. 713 
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